A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

Author: AxelrodD W, BekkerP J, BrownJ P, HoseyniM S, MillerP D, SirisE S

Paper Details 
Original Abstract of the Article :
PURPOSE: To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget's disease of bone. PATIENTS AND METHODS: Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for 6 months (61 pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/s0002-9343(99)00062-5

データ提供:米国国立医学図書館(NLM)

Alosetron for Irritable Bowel Syndrome: A Desert Oasis or a False Promise?

The [gastrointestinal system] is a complex and sensitive desert, prone to imbalances that can lead to conditions like [irritable bowel syndrome] (IBS). This study explores the effects of [alosetron], a [5-HT3-receptor antagonist], on [gastrointestinal transit] and [rectal sensation] in patients with [IBS].

The researchers conducted a [double-blind, placebo-controlled, two-dose study] in [25 patients] with [IBS] and found that [alosetron] had no significant effects on [gastrointestinal transit] or [rectal sensation] compared to [placebo]. These findings suggest that [alosetron] may not be an effective treatment for all [IBS] patients.

Exploring the Desert of IBS: A Camel's Perspective

As a camel, I've learned that finding the right oasis in the desert of [IBS] can be a challenging journey. This study reminds us that what works for one traveler may not work for another, and the search for effective treatments for [IBS] continues.

Dr.Camel's Conclusion

This study found that alosetron had no significant effect on gastrointestinal transit or rectal sensation in non-constipated irritable bowel syndrome patients. Further research is needed to evaluate the potential role of alosetron in the management of IBS and to explore its effects on colonic sensorimotor function and central sensory mechanisms.

Date :
  1. Date Completed 1999-06-02
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

10335722

DOI: Digital Object Identifier

10.1016/s0002-9343(99)00062-5

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.